Floatz logo

Tazarotene

Hand-Foot Syndrome

Dana-Farber Cancer InstituteSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Hand-Foot Syndrome cohort.

Asset / SponsorPhaseRating
Adriamycin
Swiss Cancer Institute
Phase 3BB
Mecobalamin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3B
Celecoxib
Affiliated Hospital of Qinghai University
Phase 3B
Indometacinum
National Taiwan University Hospital
Phase 2CCC
Advicor Component Niacin
First People's Hospital of Hangzhou
Phase 2CCC

View all 11 →

Same molecule, other indications

Tazarotene is also rated in:

idiopathic pulmonary fibrosisActive
CCC
Indicative · Phase 2
54 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
CC
Indicative · Phase 1/2
47 / 100
View asset →
neoplasmDormant
CC
Indicative · Phase 2
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →